Sumitomo Pharma America, Inc. $4506.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING5
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +21.5 months). See all sponsors →
Open Sumitomo Pharma America, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Nusivertib NCT04176198 |
P1/2 | Recruiting | Myelofibrosis | 240 | 2027-04-30 (+62 mo) |
| Enzomenib NCT04988555 |
P1/2 | Recruiting | Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute | 606 | 2027-06-30 (+30 mo) |
| DSP-3077 Retinal Sheet Cohort 1 NCT06891885 |
P1/2 | Recruiting | Retinitis Pigmentosa | 12 | 2028-10-31 |
| SMP3124LP NCT06526819 |
P1/2 | Recruiting | Solid Tumor | 120 | 2028-12 |
| DSP-1083 implantation NCT06753331 |
P1/2 | Recruiting | Parkinson's Disease | 25 | 2030-12-15 (+21 mo) |